Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 5/20 | 0.66 |
| ▸ | CD40 | P25942 | 3/20 | 0.64 |
| ▸ | CD40LG | P29965 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | RECQL | P46063 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.53 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.53 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.53 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10413972 | 0.88 | TIMP3 (0.58) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL11593396 | 0.88 | TIMP3 (0.63) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL30388456 | 0.85 | KMT2A (0.69) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL7613478 | 0.85 | KMT2A (0.69) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL18211300 | 0.85 | TIMP3 (0.60) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL18211297 | 0.85 | CD40 (0.52) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL14557795 | 0.85 | TIMP3 (0.71) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL11432549 | 0.84 | TIMP3 (0.55) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL11429449 | 0.84 | TIMP3 (0.55) | TIMP3CD40CD40LGKMT2ARECQL | |
| SCHEMBL11757962 | 0.83 | CD40 (0.66) | TIMP3CD40CD40LGKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8530448-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20100279958-A1 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7741312-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7361644-B2 | Specific antagonist for both E- and P-selectins | GLYCOMIMETICS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1763533-B1 | SPECIFIC ANTAGONIST FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1763533-A2 | SPECIFIC ANTAGONIST FOR BOTH E- AND P-SELECTINS | GlycoMimetics, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1685145-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GlycoMimetics, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7060685-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | GLYCOMIMETICS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050164982-A1 | Specific antagonist for both E- and P-selectins | GLYCOMIMETICS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| WO-2005054264-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005051920-A2 | SPECIFIC ANTAGONIST FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1534725-A2 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | Glycomimetics, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040254145-A1 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| WO-2003097658-A2 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | GLYCOMIMETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | SELE, SELL, SELP | TIMP3 715/4885CD40 122/4885CD40LG 81/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TIMP3 1176/4885CD40 75/4885CD40LG 65/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | TIMP3 1643/4885CD40 11/4885CD40LG 23/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TIMP3 1176/4885CD40 75/4885CD40LG 65/4885 |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | SELE, SELP, SELPLG | TIMP3 1240/4885CD40 111/4885CD40LG 116/4885 |
| US-20040254145-A1 | Compounds and methods for inhibiting selectin-mediated function | SELE, SELL, SELP | TIMP3 709/4885CD40 111/4885CD40LG 76/4885 |
| US-20100279958-A1 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | SELE, SELL, SELP | TIMP3 709/4885CD40 111/4885CD40LG 76/4885 |
| US-20050164982-A1 | Specific antagonist for both E- and P-selectins | SELE, SELP, SELPLG | TIMP3 1400/4885CD40 184/4885CD40LG 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.